文献速递帕金森病与运动障碍

MRI引导的壳核AADC基因治疗帕金森病1期试验

Magnetic resonance imaging-guided phase 1 trial of putaminal AADC gene therapy for Parkinson's disease.
PubMed 文献 · Ann Neurol · 2019-03-26

这项1期试验在15例中晚期帕金森病伴药物难治性运动波动的患者中,使用术中MRI引导双侧壳核注射VY-AADC01(表达芳香族L-氨基酸脱羧酶),分三个剂量队列评估安全性、壳核覆盖率和酶表达。结果显示给药覆盖率和PET酶活性随剂量增加,抗帕金森病药物用量减少,12个月时临床结局和患者报告的ON时间呈剂量相关改善,治疗耐受性良好。

要点

  • 术中MRI引导可优化VY-AADC01壳核递送并计算覆盖范围。
  • 壳核覆盖率、PET酶活性和药物减量随剂量增加。
  • 12个月时ON时间和生活质量呈剂量相关改善。

核心结论

  • 术中MRI监测辅助的VY-AADC01壳核递送耐受性良好,酶表达增加和临床改善呈剂量依赖性。

研究设计与样本

  • 1期开放标签剂量递增试验,纳入15例中晚期帕金森病伴药物难治性运动波动患者,分三个队列各5例。
  • 双侧壳核注射VY-AADC01并共给予钆特醇,使用术中MRI引导可视化灌注液解剖扩散并计算覆盖率。
  • 队列1剂量为8.3×10^11 vg/ml且每侧壳核≤450μl(总剂量≤7.5×10^11 vg);队列2同浓度8.3×10^11 vg/ml且每侧≤900μl(总剂量≤1.5×10^12 vg);队列3为2.6×10^12 vg/ml且每侧≤900μl(总剂量≤4.7×10^12 vg)。
  • 基线和术后6个月用18F-氟-L-二羟基苯丙氨酸PET评估酶活性,并用标准评估测量临床结局。

主要发现

  • MRI引导递增剂量VY-AADC01使壳核覆盖率分别达21%(队列1)、34%(队列2)和42%(队列3)。
  • 6个月时PET评估的酶活性相应增加13%、56%和79%,抗帕金森病药物分别减少15%、33%和42%。
  • 12个月时临床结局呈剂量相关改善,包括患者报告的ON时间(无困扰性运动障碍)分别增加1.6、3.3和1.5小时,以及生活质量改善。

临床怎么用

  • 该1期试验提示术中MRI引导可支持壳核靶向递送VY-AADC01,并显示剂量相关酶表达和临床改善信号。
  • 研究结果支持进一步开展对照试验验证VY-AADC01治疗帕金森病的疗效与安全性。

局限性

  • 为1期开放标签剂量递增试验,样本量小(15例),缺乏对照组。
  • 临床结局改善呈剂量相关但部分指标非单调(如ON时间队列3低于队列2),需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To understand the safety, putaminal coverage, and enzyme expression of adeno-associated viral vector serotype-2 encoding the complementary DNA for the enzyme, aromatic L-amino acid decarboxylase (VY-AADC01), delivered using novel intraoperative monitoring to optimize delivery. METHODS: Fifteen subjects (three cohorts of 5) with moderately advanced Parkinson's disease and medically refractory motor fluctuations received VY-AADC01 bilaterally coadministered with gadoteridol to the putamen using intraoperative magnetic resonance imaging (MRI) guidance to visualize the anatomic spread of the infusate and calculate coverage. Cohort 1 received 8.3 × 1011 vg/ml and ≤450 μl per putamen (total dose, ≤7.5 × 1011 vg); cohort 2 received the same concentration (8.3 × 1011 vg/ml) and ≤900 μl per putamen (total dose, ≤1.5 × 1012 vg); and cohort 3 received 2.6 × 1012 vg/ml and ≤900 μl per putamen (total dose, ≤4.7 × 1012 vg). (18)F-fluoro-L-dihydroxyphenylalanine positron emission tomography (PET) at baseline and 6 months postprocedure assessed enzyme activity; standard assessments measured clinical outcomes. RESULTS: MRI-guided administration of ascending VY-AADC01 doses resulted in putaminal coverage of 21% (cohort 1), 34% (cohort 2), and 42% (cohort 3). Cohorts 1, 2, and 3 showed corresponding increases in enzyme activity assessed by PET of 13%, 56%, and 79%, and reductions in antiparkinsonian medication of -15%, -33%, and -42%, respectively, at 6 months. At 12 months, there were dose-related improvements in clinical outcomes, including increases in patient-reported ON-time without troublesome dyskinesia (1.6, 3.3, and 1.5 hours, respectively) and quality of life. INTERPRETATION: Novel intraoperative monitoring of administration facilitated targeted delivery of VY-AADC01 in this phase 1 study, which was well tolerated. Increases in enzyme expression and clinical improvements were dose dependent. ClinicalTrials.gov Identifier: NCT01973543 Ann Neurol 2019;85:704-714.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Christine CW, Bankiewicz KS, Van Laar AD, et al. Magnetic resonance imaging-guided phase 1 trial of putaminal AADC gene therapy for Parkinson's disease. Ann Neurol. 2019. PMID: 30802998. doi:10.1002/ana.25450

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。